Nasdaq:PLSE
PULSE BIOSCIENCES, INC.
A clinical-stage biopharmaceutical firm investing heavily in R&D while generating negligible commercial revenue and reporting substantial net losses.
Key Metrics
Investment Thesis
Bull Case
An investor might consider this stock if they believe the company's proprietary pipeline has high potential for success and can eventually generate significant commercial value upon regulatory approval, despite current burn rates.
Bear Case
The investment case is severely weakened by a massive cash deficit, a lack of revenue diversification, and no clear path to profitability given the industry-wide challenges of clinical trial attrition rates.
About PULSE BIOSCIENCES, INC.
PULSE BIOSCIENCES, INC. (PLSE) is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious unmet medical needs, primarily operating in the United States. The company's recent financials reflect significant investment in research and development with minimal commercial revenue, characteristic of early-stage life science ventures. Key products remain in pre-commercial phases as the organization navigates the high-risk path from discovery to potential market approval.
Analysis
Management Discussion
Recent financial performance shows a widening deficit with a net loss of $72.8M compared to prior periods, driven by escalating research and development costs totaling $44.7M and general administrative expenses of $32.0M against negligible revenue generation.
Industry Overview
The biotechnology sector is characterized by high capital intensity, long development cycles, and binary outcomes where successful drug launches can yield billions while failed trials result in total loss of invested capital.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $700.0K | $0 | $0 | $350.0K |
| Cost of Revenue | $11.9M | $0 | $0 | $539.0K |
| Gross Profit | $-11.2M | $0 | $0 | $-189.0K |
| Operating Expenses | $46.8M | $43.6M | $56.3M | $76.8M |
| Operating Income | $-58.1M | $-43.6M | $-56.3M | $-76.9M |
| R&D | $20.8M | $27.8M | $32.3M | $44.7M |
| G&A | $14.0M | $15.8M | $23.9M | $32.0M |
| Stock-Based Comp | $5.2M | $7.2M | $13.6M | $21.5M |
| Depreciation | $690.0K | $542.0K | $512.0K | $406.0K |
| Amortization | $665.0K | $665.0K | $666.0K | $665.0K |
| Other OpEx | $12.0M | $0 | $0 | $0 |
| Non-Operating Income | $-448.0K | $1.4M | $2.7M | $149.7M |
| Pre-Tax Income | $-58.5M | $-42.2M | $-53.6M | $72.8M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-58.5M | $-42.2M | $-53.6M | $72.8M |
| Discontinued Ops | $0 | $0 | $0 | $-145.6M |
| Net Income | $-58.5M | $-42.2M | $-53.6M | $-72.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-58.5M | $-42.2M | $-53.6M | $-72.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $62.1M | $45.3M | $119.4M | $83.4M |
| Cash & Equivalents | $61.1M | $44.4M | $118.0M | $80.7M |
| Accounts Receivable | $0 | — | — | $274.0K |
| Inventory | $0 | — | — | $136.0K |
| Prepaid Expenses | $1.0M | $963.0K | $1.4M | $2.3M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $15.7M | $13.8M | $13.0M | $11.1M |
| PP&E (Net) | $2.0M | $1.5M | $1.2M | $1.1M |
| Goodwill | $2.8M | $2.8M | $2.8M | $2.8M |
| Operating Leases | $8.1M | $7.3M | $7.2M | $6.0M |
| Other LT Assets | $2.9M | $2.3M | $1.9M | $1.3M |
| Total Assets | $77.9M | $59.2M | $132.5M | $94.5M |
| Current Liabilities | $6.0M | $6.7M | $10.1M | $7.9M |
| Accounts Payable | $1.6M | $1.8M | $1.7M | $2.8M |
| Current Leases | $896.0K | $1.1M | $1.4M | $1.6M |
| Deferred Revenue | $0 | — | — | — |
| Other Current Liab | $917.0K | $0 | $0 | $0 |
| Long-Term Liabilities | $74.1M | $8.1M | $7.5M | $6.0M |
| LT Operating Leases | $9.1M | $8.1M | $7.5M | $6.0M |
| Other LT Liab | $65.0M | $0 | $0 | $0 |
| Total Liabilities | $80.1M | $14.8M | $17.6M | $13.9M |
| Shareholders' Equity | $-2.2M | $44.4M | $114.9M | $80.7M |
| Retained Earnings | $-294.7M | $-336.9M | $-390.5M | $-463.3M |
| AOCI | $0 | $0 | $0 | — |
| Total L&E | $77.9M | $59.2M | $132.5M | $94.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-58.5M | $-42.2M | $-53.6M | $-72.8M |
| Non-Cash Adjustments | $13.0M | $9.3M | $14.9M | $21.0M |
| Working Capital Changes | $-1.5M | $-126.0K | $2.3M | $-2.4M |
| Cash from Operations | $-47.0M | $-33.0M | $-36.3M | $-54.1M |
| Capital Expenditures | $401.0K | $121.0K | $125.0K | $315.0K |
| Cash from Investing | $-401.0K | $-121.0K | $-125.0K | $-335.0K |
| Cash from Financing | $79.9M | $16.4M | $110.1M | $17.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $32.5M | $-16.8M | $73.7M | $-37.3M |
| Beginning Cash | $28.6M | $61.1M | $44.4M | $118.0M |
| Ending Cash | $61.1M | $44.4M | $118.0M | $80.7M |
Frequently Asked Questions
How does PULSE BIOSCIENCES, INC. make money?
The company's financial profile indicates a single primary segment focused on drug discovery and development, evidenced by $44.7M in research and development expenses against only $0.35M in total revenue for the latest period.
What are the main risks for PLSE?
The company faces extreme financial risk due to a cumulative net loss of over $72M, severe liquidity pressure from a $37.3M decrease in cash, and the high probability of failure inherent in bringing new drugs to market.
What is PLSE's competitive advantage?
PULSE BIOSCIENCES leverages proprietary intellectual property rights to its novel therapeutic candidates and utilizes a lean operational model with minimal fixed assets to preserve cash flow during early-stage clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.